FDA Approves Piqray for Adv. HR+, HER2- BC w/ PIK3CA Mutation

Moderators

FDA Approves Piqray to Treat Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation
May 29, 2019
FDA approves Piqray in combination with Faslodex to treat metastatic and advanced-stage, hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation that has grown after hormonal therapy treatment in postmenopausal women and men. Read more...